News articles about AbbVie (NYSE:ABBV) have trended somewhat negative this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AbbVie earned a daily sentiment score of -0.01 on Accern’s scale. Accern also gave press coverage about the company an impact score of 43.8859261196754 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- AbbVie’s HCV Combo Drug Mavyret Clinches Approval in Canada (mrtopstep.com)
- AbbVie : s MAVIRET Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes (4-traders.com)
- Lam Research Corporation (LRCX) Shares Sold by Pioneer Investment Management Inc (currenthollywood.com)
- AbbVie’s HCV Combo Drug Mavyret Clinches Approval in Canada (zacks.com)
- AbbVie’s HCV Combo Drug Mavyret Clinches Approval in Canada – Nasdaq (nasdaq.com)
ABBV has been the subject of a number of recent analyst reports. Vetr downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating and set a $71.84 price target for the company. in a report on Monday, May 15th. Jefferies Group LLC restated a “buy” rating on shares of AbbVie in a report on Friday, May 26th. Societe Generale upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. BidaskClub downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $85.00 price target on shares of AbbVie in a research report on Thursday, August 3rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. AbbVie currently has an average rating of “Buy” and a consensus target price of $76.02.
AbbVie (ABBV) traded up 0.16% during midday trading on Friday, hitting $69.96. 4,016,367 shares of the stock traded hands. The company has a market cap of $111.52 billion, a PE ratio of 17.21 and a beta of 1.50. The company’s 50-day moving average is $71.72 and its 200-day moving average is $67.10. AbbVie has a one year low of $55.06 and a one year high of $75.04.
AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The business had revenue of $6.94 billion during the quarter, compared to analyst estimates of $6.93 billion. During the same period last year, the business earned $1.26 EPS. The business’s revenue was up 7.6% on a year-over-year basis. Equities research analysts expect that AbbVie will post $5.52 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th were paid a dividend of $0.64 per share. The ex-dividend date was Wednesday, July 12th. This represents a $2.56 dividend on an annualized basis and a yield of 3.66%. AbbVie’s dividend payout ratio (DPR) is 62.90%.
In other AbbVie news, insider Laura J. Schumacher sold 79,800 shares of the stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $70.00, for a total transaction of $5,586,000.00. Following the transaction, the insider now directly owns 187,625 shares in the company, valued at approximately $13,133,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Richard A. Gonzalez sold 87,899 shares of the stock in a transaction on Friday, August 4th. The shares were sold at an average price of $71.02, for a total transaction of $6,242,586.98. Following the transaction, the chairman now owns 342,353 shares in the company, valued at $24,313,910.06. The disclosure for this sale can be found here. Insiders have sold a total of 490,491 shares of company stock worth $34,684,639 over the last quarter. 0.23% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This piece was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/20/abbvie-nyseabbv-receives-daily-media-sentiment-rating-of-0-01-updated-updated-updated.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.